These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36154577)

  • 1. CRISPR/Cas9 Tool for MicroRNAs Editing in Cardiac Development, Function, and Disease.
    Abkhooie L; Saberianpour S
    Microrna; 2023; 12(1):13-21. PubMed ID: 36154577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research.
    Aquino-Jarquin G
    Cancer Res; 2017 Dec; 77(24):6812-6817. PubMed ID: 29208606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient Mutagenesis of Marek's Disease Virus-Encoded microRNAs Using a CRISPR/Cas9-Based Gene Editing System.
    Luo J; Teng M; Zai X; Tang N; Zhang Y; Mandviwala A; Reddy VRAP; Baigent S; Yao Y; Nair V
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32325942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus.
    Liang Z; Qin Z; Riker AI; Xi Y
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1400-1405. PubMed ID: 33092788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas: A powerful tool for gene function study and crop improvement.
    Zhang D; Zhang Z; Unver T; Zhang B
    J Adv Res; 2021 Mar; 29():207-221. PubMed ID: 33842017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular evolution and functional modification of plant miRNAs with CRISPR.
    Deng F; Zeng F; Shen Q; Abbas A; Cheng J; Jiang W; Chen G; Shah AN; Holford P; Tanveer M; Zhang D; Chen ZH
    Trends Plant Sci; 2022 Sep; 27(9):890-907. PubMed ID: 35165036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-Type-Specific CRISPR Activation with MicroRNA-Responsive AcrllA4 Switch.
    Hirosawa M; Fujita Y; Saito H
    ACS Synth Biol; 2019 Jul; 8(7):1575-1582. PubMed ID: 31268303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Identify Myeloid Differentiation-Related MiRNAs Response to ATRA Induction by RNA Sequencing and CRISPR/Cas9 Gene Editing].
    Wang LY; Lin RZ; Jiang PF; Zhang Y; Li JZ; Chen YW; Hu JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):339-347. PubMed ID: 33812397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrogation of Functional miRNA-Target Interactions by CRISPR/Cas9 Genome Engineering.
    Michaels YS; Wu Q; Fulga TA
    Methods Mol Biol; 2017; 1580():79-97. PubMed ID: 28439828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs.
    Kurata JS; Lin RJ
    RNA; 2018 Jul; 24(7):966-981. PubMed ID: 29720387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 System to Knockdown MicroRNA In Vitro and In Vivo.
    Yi B; Larter K; Xi Y
    Methods Mol Biol; 2021; 2300():133-139. PubMed ID: 33792878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-Mediated Knockout of MicroRNA-744 Improves Antibody Titer of CHO Production Cell Lines.
    Raab N; Mathias S; Alt K; Handrick R; Fischer S; Schmieder V; Jadhav V; Borth N; Otte K
    Biotechnol J; 2019 May; 14(5):e1800477. PubMed ID: 30802343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing Rice Mutants Using CRISPR/Cas9-Based Genome Editing Technology.
    Xu K; Li Y
    Methods Mol Biol; 2022; 2400():11-19. PubMed ID: 34905186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
    Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
    Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessing abundance and specificity of different types of sgRNA targeting miRNA precursors].
    Liu HL; Shen Y; Gao Y; Zhou L; Han XS; Zhao CZ; Yang GJ; Chen YL; Yang H; Xie SS
    Yi Chuan; 2018 Jul; 40(7):561-571. PubMed ID: 30021719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.
    Li Y; Glass Z; Huang M; Chen ZY; Xu Q
    Biomaterials; 2020 Mar; 234():119711. PubMed ID: 31945616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch.
    Hirosawa M; Fujita Y; Parr CJC; Hayashi K; Kashida S; Hotta A; Woltjen K; Saito H
    Nucleic Acids Res; 2017 Jul; 45(13):e118. PubMed ID: 28525578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.